JMP Securities Upgrades Vitae Pharmaceuticals (VTAE) to Market Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/30/2026
- Wall St advances as Microsoft results ease AI spending fears
- Microsoft surges 8% on strong revenue outlook, maintained capex guidance
- Meta sinks 8% after Q3 revenue forecast misses Wall Street estimates
- AI wizkid Leopold Aschenbrenner forced to sell entire portfolio after rout
- Microsoft rally lifts stocks, 30-year Treasury yield hits 19-year peak
- Crude Inventory Fell 7.2 Million Barrels Last Week - EIA
- SoFi Technologies (SOFI) Tops Q2 EPS by 1c ; Offers Guidance
- Wall Street closes down sharply after Fed holds rates unchanged
- How will the S&P 500 react to today’s FOMC? JPM lays out the playbook
- Grant Thornton Advisors to buy CBIZ in $5 billion deal, expand US accounting reach
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
- After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK
- After-Hours Stock Movers: GOOGL, TSLA, NOW, IBM, TXN, MOH, URI
Vitae Pharmaceuticals (VTAE) PT Raised to $23 at Wedbush
March 18, 2016 6:42 AM EDTWedbush analyst Liana Moussatos reiterated an Outperform rating and raised her price target on Vitae Pharmaceuticals (NASDAQ: VTAE) to $23.00 (from $20.00) after proof-of-concept for RAR-Related Orphan Receptor -t ( ROR t) inhibition was achieved, in their view.
Moussatos commented: "The randomized, double blind multiple ascending dose (MAD) Part II trial tested once-daily, orally-dosed... More
Stifel Upgrades Vitae Pharmaceuticals (VTAE) to Buy, $15 PT
March 17, 2016 6:27 AM EDTStifel upgraded Vitae Pharmaceuticals (NASDAQ: VTAE) from Hold to Buy with a price target of $15.00, saying 43742 Data shows drug potential is significant, and toxic signal seems manageable.
Analyst Thomas Shrader commented, "Vitae release its eagerly awaited topline data for VTP-43742 and the drug is clearly active.... More
Vitae Pharma (VTAE) Announces Statistically Significant Data from VTP-43742 Phase 2a PoC Trial in Psoriatic Patients
March 16, 2016 4:06 PM EDTVitae Pharmaceuticals, Inc. (Nasdaq: VTAE) announced positive top-line results from its Phase 2a proof-of-concept clinical trial of VTP-43742 in psoriatic patients. VTP-43742 is Vitae's wholly owned, first-in-class, orally active RORt inhibitor with the potential to transform the treatment of multiple autoimmune disorders, including... More
Vitae Pharmaceuticals (VTAE) trading halted with news pending
March 16, 2016 4:01 PM EDTVitae Pharmaceuticals (NASDAQ: VTAE) trading halted with news pending.
... More